AKBA
Akebia Therapeutics, Inc.
Key Financials
Net Income
$-5345000
↑ 92.3%
Revenue
$236.2M
↑ 47.5%
Operating Income
$23.5M
↑ 146.6%
EPS (Diluted)
$-0.02
↑ 93.9%
Total Assets
$376.6M
↑ 70.6%
Total Liabilities
$344.0M
↑ 27.5%
Shareholders' Equity
$32.6M
↑ 166.3%
Long-term Debt
$48.3M
↑ 24.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
| DEF 14A | 4/28/2026 | View on SEC |
| PRE 14A | 4/15/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 3 | 4/3/2026 | View on SEC |
| 8-K | 4/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AKBA |
| Company Name | Akebia Therapeutics, Inc. |
| CIK | 1517022 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-871-2098 |